Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

Blood (2024) 144 (22): 2360–2363.

https://doi.org/10.1182/blood.2024025834

Published: 2024

Includes: Supplemental data

Journal Articles

A Single-Arm, Phase II Study of Acalabrutinib As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Mantle Cell Lymphoma

Michael T. Tees, Nakhle S Saba, Suman Kambhampati, Ian W. Flinn

Blood (2024) 144 (Supplement 1): 6321.

https://doi.org/10.1182/blood-2024-193140

Published: 2024

Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein

Blood (2022) 140 (Supplement 1): 3333–3335.

https://doi.org/10.1182/blood-2022-156564

Published: 2022

Journal Articles

Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

Blood (2021) 138 (Supplement 1): 65.

https://doi.org/10.1182/blood-2021-146597

Published: 2021

Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Blood (2021) 138 (Supplement 1): 3726.

https://doi.org/10.1182/blood-2021-147460

Published: 2021

Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 3725.

https://doi.org/10.1182/blood-2021-147258

Published: 2021

Journal Articles

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Javier Pinilla Ibarz, Wojciech Jurczak, Suman Kambhampati, Ewa Lech Maranda, Tomasz Wróbel, Jeff P. Sharman, Syed F. Zafar, Marc Hoffmann, Scott F. Huntington, Ryan Jacobs, Osnat Bairey, Chris Rowland, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Owen A. O'Connor, Ian W. Flinn

Blood (2021) 138 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2021-151292

Published: 2021

Journal Articles

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Mikkael A. Sekeres, Larisa Girshova, Vadim A Doronin, Maria Diez-Campelo, David Valcarcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argiris Symeonidis, Achilles Anagnostopoulos, Eduardo Ciliao Munhoz, Uwe Platzbecker, Valeria Santini, Robert J. Fram, Ying Yuan, Douglas V. Faller, Lionel Ades

Blood (2021) 138 (Supplement 1): 242.

https://doi.org/10.1182/blood-2021-146154

Published: 2021

Journal Articles

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Blood (2021) 137 (20): 2817–2826.

https://doi.org/10.1182/blood.2020007376

Published: 2021

Includes: Supplemental data

Journal Articles

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Minoo Battiwalla, MD, Carlos Bachier, MD, Vikas Bhushan, MD, Michael J. Eckrich, MD MPH, Alireza Eghtedar, MD, Haydar Frangoul, MD, Suman Kambhampati, MD, Shahbaz Malik, MD, Peter A. McSweeney, MD, Jeremy Pantin, MBBS, Aravind Ramakrishnan, MD, Hana Safah, MD, Paul J Shaughnessy, MD, Betsy Blunk, BSN, RN, BMTCN, Tonya Cox, BSN, RN, Rocky Billups, MS, Charles F. Lemaistre, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-139121

Published: 2020

Journal Articles

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Ian W. Flinn, MD PhD, David Andorsky, MD PhD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn Kolibaba, MD, Habte A. Yimer, MD, John M. Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Daniel Dingfeng Jiang, MD PhD, John C. Pesko, PhD, Tamas Vizkelety, MD, Simon Sharmokh, MPH, PharmD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137406

Published: 2020

Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood (2020) 136 (Supplement 1): 37–39.

https://doi.org/10.1182/blood-2020-134783

Published: 2020

Journal Articles

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Esther Natalie Oliva, MD, Suman Kambhampati, MD, Albert Oriol, Ignazia La Torre, Barry Skikne, MD, C.L. Beach, PharmD, Keshava Kumar, PhD, Qian Dong, DrPH, Clara Chen, Sandip Ranjan, MTech, Zephirin Kiendrebeogo, Msc, PMP, Thorsten Braun, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137562

Published: 2020

Journal Articles

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Charles F. Lemaistre, MD, Ju-Hsien Chao, DO, Tonya Cox, BSN, RN, Jose Carlos Cruz, MD, William B. Donnellan, MD, Alireza Eghtedar, MD, Jared Holder, MA, Suman Kambhampati, MD, Shahbaz Malik, Michael B. Maris, MD, Marcello Rotta, MD, Frank Thomas Slovick, MD, Minoo Battiwalla, MD

Blood (2019) 134 (Supplement_1): 4780.

https://doi.org/10.1182/blood-2019-130640

Published: 2019

Journal Articles

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

Saqib Abbasi, MD, Brian McClune, DO, Leyla Shune, MD, Suman Kambhampati, MD, Saqib Abbasi, MD

Blood (2019) 134 (Supplement_1): 3431.

https://doi.org/10.1182/blood-2019-131622

Published: 2019

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Jesus G. Berdeja, MD, Tara K. Gregory, MD, Suman Kambhampati, MD, Bertrand M. Anz, III, MD, Stefano R. Tarantolo, MD, Anthony A. Meluch, MD, Jeffrey V. Matous, MD

Blood (2019) 134 (Supplement_1): 603.

https://doi.org/10.1182/blood-2019-130277

Published: 2019

Journal Articles

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Jeff P. Sharman, MD, David Andorsky, MD, Jason M. Melear, MD, Sudhir Manda, MD, Bertrand M. Anz, III, MD, Kathryn S. Kolibaba, MD, Habte A Yimer, MD, John M Burke, MD, Suzanne R. Fanning, DO, Jay Courtright, MD, Miguel Islas-Ohlmayer, MD, Suman Kambhampati, MD, Abdullah Al Masud, PhD, Todd Zimmerman, Jacqueline Nielsen, PhD, Tamas Vizkelety, Dingfeng Jiang, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 3042.

https://doi.org/10.1182/blood-2019-127408

Published: 2019

Journal Articles

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Blood (2018) 132 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2018-99-117231

Published: 2018

Journal Articles

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Robert M Rifkin, MD, Ralph V. Boccia, MD, Suman Kambhampati, MD, Joshua R Richter, MD, Saad Z Usmani, MD, Jack Aiello, EE, MS, BS, Brittany Sickler, BA, BS, Magdalena Schoeneich, MBA, MS, Bingxia Wang, PhD, Susan Zelt, PhD, Presley Whidden, MS, Lawrence E Dollar, PharmD, MS, Liviu Niculescu, MD, Stephen J Noga, MD

Blood (2017) 130 (Supplement 1): 5407.

https://doi.org/10.1182/blood.V130.Suppl_1.5407.5407

Published: 2017

NARROW

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort

A Single-Arm, Phase II Study of Acalabrutinib As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Mantle Cell Lymphoma

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Lenalidomide and Eltrombopag for Treatment in Low or Intermediate Risk Myelodysplastic Syndrome: Result of a Phase 2 Study Combination Clinical Trial

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)

Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial

Center Effects on Outcomes in the Treatment of Acute Myelogenous Leukemia (AML): A Multilevel, Community-Based, Case-Controlled Study

Inpatient Hospitalization's Associated Cost and Mortality for Myeloma Patients Undergoing Autologous Stem Cell Transplant: A 13-Year Analysis of the National Inpatient Sample

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed with Multiple Myeloma (MM)

Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study

Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only